SCHEMBL693167

SCHEMBL693167

Nc1ccc(-c2ccc(OCCc3ccc(Cl)cc3)nn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.41
HTR2A P28223 3/20 0.38
MCHR1 Q99705 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
BCHE P06276 2/20 0.38
ACHE P22303 2/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
TAAR1 Q96RJ0 1/20 0.38
CHRM1 P11229 2/20 0.37
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CDK2 P24941 1/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
ELOVL1 Q9BW60 1/20 0.35
ALDH1A1 P00352 1/20 0.35
DHFR P00374 1/20 0.35
GPR84 Q9NQS5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL693164 0.85 MEN1 (0.42) MEN1KMT2ABCHEACHENPC1
SCHEMBL692988 0.82 CTRC (0.46) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL692557 0.78 CXCL12 (0.51) MEN1KMT2AACHETAAR1
SCHEMBL3242646 0.77 RHEB (0.36) HTR2AMCHR1MEN1KMT2ABCHE
SCHEMBL11181089 0.77 TAAR1 (0.44) MAOBMEN1KMT2ANPC1RAB9A
SCHEMBL30354806 0.77 TAAR1 (0.44) MAOBMEN1KMT2ANPC1RAB9A
SCHEMBL693064 0.76 PPARA (0.47) MEN1KMT2AMAPTPTGS2
SCHEMBL1370818 0.74 MAPT (0.44) MEN1KMT2AMAPT
SCHEMBL692593 0.74 NR4A2 (0.48) MEN1KMT2A
SCHEMBL692519 0.74 APP (0.40) MAOBMCHR1MEN1KMT2ATAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560654-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2013-02-27 EP disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH 2012-05-24 US disclosed
EP-2421368-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES Institute for OneWorld Health (US) 2012-02-29 EP disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives INSTITUTE FOR ONEWORLD HEALTH 2011-11-24 US disclosed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO disclosed
WO-2011133600-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2011-10-27 WO disclosed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO disclosed
WO-2010123822-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES INSTITUTE FOR ONEWORLD HEALTH (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129858-A1 COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES CFTR, PKD1, PKD2 MAOB 4679/4885HTR2A 1280/4885MCHR1 3878/4885
US-20110288093-A1 Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives SCN1A, CLIC1, CLCN2 MAOB 2474/4885HTR2A 1172/4885MCHR1 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.